Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;51(2):367-378.
doi: 10.1016/j.ecl.2021.11.019. Epub 2022 May 4.

Novel Therapeutics for Advanced Differentiated Thyroid Cancer

Leedor Lieberman  1 , Francis Worden  2
Affiliations
Review

Novel Therapeutics for Advanced Differentiated Thyroid Cancer

Leedor Lieberman et al. Endocrinol Metab Clin North Am. 2022 Jun.

Abstract

The current treatments for radioactive iodine (RAI) -refractory differentiated thyroid cancer (DTC) are evolving as cancer genomics are further understood. Multitargeted tyrosine kinase inhibitors are the first-line therapy for symptomatic or progressive disease; however, considerable adverse effects have spurred the development of targeted therapies for redifferentiation of iodine avidity and the treatment of RAI-refractory DTC. Next-generation sequencing allows for the use of tumor-targeted therapeutics, such as MEK1/2, BRAF, RET, and NTRK inhibitors. Immunotherapy is also under investigation as a therapeutic option for this disease.

Keywords: Cancer; Immunotherapy; Lenvatinib; Next-generation sequencing; Radioactive iodine; Refractory; Sorafenib; Thyroid.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr L. Lieberman receives support from grant T32DK007245-45 from the National Institute of Diabetes and Digestive and Kidney Diseases. Dr F. Worden: Exilexis, Eisai, Pfizer, Merck, BMS, CUE Biopharmaceuticals.

Publication types

MeSH terms